• Phil Taylor
• 03 Jan, 2019

The decision comes ahead of data readouts for two of the clinical candidates – mavacamten and MYK-491 – within the next 12 to 24 months, and comes as Sanofi is in the midst of a radical restructuring of its business and refocusing of its research priorities into areas such as cancer. The Californian biotech put a positive spin on the development of course, and its chief executive Tassos Gianakakos said regaining rights to the programmes.
Read more...